Dr Thomas Seisen talks about treatment option...

When is urodynamic testing truly necessary, and when can it be avoided? How can clinicians make the right decision for each patient?In this episode, Prof. Enrico Finazzi Agrò (IT) is joined by Prof. Salvador Arlandis Guzmán (ES), Prof. Tufan Tarcan (TR) and Prof. Maurizio Serati ...  Show more

In this episode, UROONCO PCa associate editor Dr. Pawel Rajwa speaks with Prof. Matthew Cooperberg from the University of California about genomic and AI-based risk classifiers in localised prostate cancer and how these tools are helping to personalise patient care.They discuss h ...  Show more

Stay up-to-date on the latest advancements and treatment strategies in the field of genitourinary oncology. In this episode of BackTable Urology, guest host Dr. Bogdana Schmidt, a urologic oncologist from the University of Utah, discusses takeaways from ASCO 2024 with Dr. Petros ...  Show more

New FDA-approved therapies for BCG-refractory non-muscle invasive bladder cancer (NMIBC)–where do they fit in the treatment algorithm, and how do you administer them? This installment of the 2025 NMIBC Creator Weekend™ series features host Dr. Bogdana Schmidt, assistant professor ...  Show more

AUA Guidelines: Treatment Of Non - Metastatic Muscle - Invasive Bladder Cancer Guest: Jeffrey M Holzbeierlein, MD Outline: Segment #1: Guideline Statement 9-Patients who have not received cisplatin-based NAC and have pT3-4 and/or N= disease at cystectomy should receive adjuvant c ...  Show more